A meta-analysis of the effects of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on insulin sensitivity in hypertensive patients without diabetes

Diabetes Research and Clinical Practice

Volumn 107, Issue 3, 2015, Pages 415-423

  Yang, Yue ^a,b   Wei, Ri Bao ^a   Wang, Zi Cheng ^a   Wang, Na ^a   Gao, Yu Wei ^a   Li, Min Xia ^a   Qiu, Qiang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

^b NANKAI UNIVERSITY   (China)

Author keywords

Angiotensin converting enzyme inhibitors; Angiotensin receptor blockers; Insulin sensitivity; Meta analysis

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; GLUCOSE; INSULIN; GLUCOSE BLOOD LEVEL;

ABSENCE OF SIDE EFFECTS; ARTICLE; BLOOD PRESSURE REGULATION; COMPARATIVE EFFECTIVENESS; DIASTOLIC BLOOD PRESSURE; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERTENSION; INSULIN BLOOD LEVEL; INSULIN SENSITIVITY; META ANALYSIS; OBSERVATION; RISK ASSESSMENT; RISK FACTOR; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; BLOOD PRESSURE; DRUG EFFECTS; INSULIN RESISTANCE; METABOLISM;

ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD GLUCOSE; BLOOD PRESSURE; HUMANS; HYPERTENSION; INSULIN RESISTANCE;

EID: 84924108263     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.11.007     Document Type: Article

References (27)

1. Odegaard J.I., Chawla A. Pleiotropic actions of insulin resistance and inflammation in metabolic homeostasis. Science 2013, 339(6116):172-177.
2. Park M.H., Kinra S., Ward K.J., White B., Viner R.M. Metformin for obesity in children and adolescents: a systematic review. Diabetes Care 2009, 32(9):1743-1745.
3. Scheen A.J., Lefebvre P.J. Troglitazone: antihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 1999, 22(9):1568-1577.
4. Staels B., Fruchart J.C. Therapeutic roles of peroxisome proliferator-activated receptor agonists. Diabetes 2005, 54(8):2460-2470.
5. Yang Y., Wei R.B., Xing Y., Tang L., Zheng X.Y., Wang Z.C., et al. A meta-analysis of the effect of angiotensin receptor blockers and calcium channel blockers on blood pressure: glycemia and the HOMA-IR index in non-diabetic patients. Metabolism 2013, 62(12):1858-1866. (Clinical and Experimental).
6. Michel M.C., Foster C., Brunner H.R., Liu L. A systematic comparison of the properties of clinically used angiotensin II type 1 receptor antagonists. Pharmacol Rev 2013, 65(2):809-848.
7. James P.A., Oparil S., Carter B.L., Cushman W.C., Dennison-Himmelfarb C., Handler J., et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA 2014, 311(5):507-520.
8. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2005; 28:S4-S36.
9. Higgins J., Green S. Cochrane handbook for systematic reviews of interventions version 5.0. 2 2010, The Cochrane Collaboration, 2009, Available from www.cochrane-handbook.org [updated September 2009].
10. Wong S.S., Wilczynski N.L., Haynes R.B. Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE. J Med Libr Assoc 2006, 94(1):41-47.
11. Mancia G., Fagard R., Narkiewicz K., Redon J., Zanchetti A., Bohm M., et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. Blood Press 2013, 22(4):193-278.
12. Egger M., Davey Smith G., Schneider M., Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315(7109):629-634.
13. Begg C.B., Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994, 50(4):1088-1101.
14. Fogari R., Zoppi A., Salvadeo S.A.T., Mugellini A., Lazzari P., Santoro T., et al. Fibrinolysis and insulin sensitivity in imidapril and candesartan (FISIC study) recipients with hypertension. Hypertens Res 2011, 34(4):509-515.
15. Koh K.K., Quon M.J., Lee Y., Han S.H., Ahn J.Y., Chung W.J., et al. Additive beneficial cardiovascular and metabolic effects of combination therapy with ramipril and candesartan in hypertensive patients. Eur Heart J 2007, 28(12):1440-1447.
16. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Koh Y., et al. Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs. Int J Cardiol 2010, 140(1):73-81.
17. Yavuz D., Koc M., Toprak A., Akpinar I., Velioglu A., Deyneli O., et al. Effects of ACE inhibition and AT(1)-receptor antagonism on endothelial function and insulin sensitivity in essential hypertensive patients. J Renin Angiotensin Aldosterone Syst 2003, 4(3):197-203.
18. Reaven G.M. Relationships among insulin resistance, type 2 diabetes, essential hypertension, and cardiovascular disease: similarities and differences. J Clin Hypertens (Greenwich) 2011, 13(4):238-243.
19. Henriksen E.J., Jacob S., Augustin H.J., Dietze G.J. Glucose transport activity in insulin-resistant rat muscle-effects of angiotensin-converting enzyme inhibitors and bradykinin antagonism. Diabetes 1996, 45:S125-S128.
20. Fogari R., Zoppi A., Corradi L., Lazzari P., Mugellini A., Lusardi P. Comparative effects of lisinopril and losartan on insulin sensitivity in the treatment of non diabetic hypertensive patients. Br J Clin Pharmacol 1998, 46:467-471.
21. Abbasi F., McLaughlin T., Lamendola C., Reaven G.M. The relationship between glucose disposal in response to physiological hyperinsulinemia and basal glucose and free fatty acid concentrations in healthy volunteers. J Clin Endocrinol Metab 2000, 85(3):1251-1254.
22. Facchini F.S., DoNascimento C., Reaven G.M., Yip J.W., Ni X.P., Humphreys M.H. Blood pressure: sodium intake, insulin resistance, and urinary nitrate excretion. Hypertension 1999, 33(4):1008-1012.
23. Reaven G.M., Lithell H., Landsberg L. Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. N Engl J Med 1996, 334(6):374-381.
24. Reaven G.M. The kidney: an unwilling accomplice in syndrome X. Am J Kidney Dis 1997, 30(6):928-931.
25. Dahlof B., Devereux R.B., Kjeldsen S.E., Julius S., Beevers G., de Faire U., et al. Cardiovascular morbidity and mortality in the Losartan Intervention for endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
26. Yusuf S., Sleight P., Pogue J., Bosch J., Davies R., Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000, 342(3):145-153.
27. Cheng J., Zhang W., Zhang X., Han F., Li X., He X., et al. Effect of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers on all-cause mortality, cardiovascular deaths, and cardiovascular events in patients with diabetes mellitus: a meta-analysis. JAMA Intern Med 2014, 174(5):773-785.